Unique Functional mAbs to Deplete Plasma Cells in Mice

Role of BAFF and APRIL in Immune Regulation and Innovative Antibodies

The B cell-stimulating molecules, BAFF and APRIL, are critical factors in the maintenance of the B cell pool and humoral immunity. BAFF is a transmembrane protein processed to a soluble cytokine, existing as either trimers or as a 60-mer assembly. These forms signal through different receptors, with the 60-mer engaging TACI and BCMA, unlike the 3-mer. APRIL, on the other hand, binds to TACI, BCMA, and heparan sulfate proteoglycans, influencing B cell homeostasis and plasma cell survival. These interactions are vital for class-switch recombination and the establishment of long-lived plasma cells in the bone marrow.

AdipoGen Life Sciences has developed several monoclonal antibodies targeting these pathways. The anti-BAFF (mouse), mAb (blocking) (Sandy-2) is a potent inhibitor of mouse BAFF, preventing its binding to BAFF-R and TACI, and effectively depleting B cells in vivo. Similarly, the anti-APRIL (mouse), mAb (rec.) (blocking) (Apry-1-1) inhibits APRIL’s interaction with BCMA and TACI, promoting its binding to HSPGs and offering atheroprotection. These antibodies are crucial for studying the roles of BAFF and APRIL in autoimmune diseases and potential therapeutic applications.

Additionally, AdipoGen Life Sciences’ anti-APRIL (mouse), mAb (blocking) (Centotto-1) (preservative free) is a monoclonal antibody that recognizes mouse APRIL and works specifically in IP and Functional Application. The antibody depletes mouse APRIL in vivo and is available without preservatives.

Advanced ELISA Kit and Implications for Disease Management

The BAFF, Soluble (human) ELISA Kit (hypersensitive) is another significant tool, providing a hypersensitive assay for quantifying human BAFF levels in various biological samples. This kit is renowned for its specificity and sensitivity, making it a preferred choice for contract research organizations.

Recent studies have highlighted the involvement of the BAFF/APRIL axis in inflammation-induced preterm birth, with BAFF enhancing inflammatory responses and APRIL mitigating them. This discovery opens new therapeutic possibilities for managing preterm birth risks.

Research Insights, Future Directions, and Conclusion

Furthermore, research published in PNAS by Pascal Schneider’s lab underscores the necessity of dual inhibition of BAFF and APRIL to effectively target plasma cells across different tissues. This approach, utilizing AdipoGen’s antibodies, has shown significant results in depleting IgA plasma cells in the gut, demonstrating the potential of these reagents in therapeutic settings.

In conclusion, the development of these unique functional antibodies and assays represents a significant advancement in autoimmune disease research. By targeting the BAFF and APRIL pathways, researchers can explore new therapeutic strategies for conditions like systemic lupus erythematosus, Sjögren’s syndrome, and rheumatoid arthritis, as well as their roles in cancer and cardiovascular diseases. These innovations not only enhance our understanding of immune regulation but also pave the way for novel treatments in autoimmune and inflammatory diseases.

NEW & UNIQUE anti-APRIL (mouse), mAb (blocking) (Centotto-1) (preservative free)